CCL2 and metabolic dysfunction-associated steatotic liver disease: We demonstrated that 2,5-DHBA competed with CCL2 for binding to CCR2, thereby altering CCL2 production, suppressing NF-κB activation, and reducing inflammatory cell infiltration, ultimately slowing MASLD progression in HFD-fed mice.